Zenas BioPharma, Inc. (ZBIO) AI Stock Analysis

• Market Cap: $1.34B
• Dividend Yield: N/A
• Average Volume (3M): 654.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.31
• Revenue Growth: N/A
• EPS Growth: -38.04%
• Country: US
• Employees: 130
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -4.54
• Shares Outstanding: 57,361,260
• 10 Day Avg. Volume: 374,900
• 30 Day Avg. Volume: 654,638
• PEG Ratio: -0.03
• Price to Book (P/B): 6.71
• Price to Sales (P/S): 162.41
• P/FCF Ratio: -9.42
• Enterprise Value/Market Cap: 0.70
• Enterprise Value/Revenue: 93.40
• Enterprise Value/Gross Profit: -24.55
• Enterprise Value/Ebitda: -4.41
• 1Y Price Target: $43.50
• Price Target Upside: 86.14% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -4.5
• Revenue Forecast (FY): $9.38M

• Rating: 54 Neutral
• Price Target: $23.50 ▲(0.56% Upside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is held back primarily by very weak profitability and heavy ongoing cash burn, despite a low-debt balance sheet. A strong positive Phase 3 readout with planned regulatory filings provides a meaningful upside catalyst, while technical indicators are mixed-to-soft and valuation metrics are constrained by losses.

Positive Factors

Phase 3 success & regulatory path

A positive, registration-directed Phase 3 with planned FDA and EMA filings materially de-risks the clinical and regulatory pathway for obexelimab. This creates a durable near-term commercial opportunity and a clear milestone timeline that can transform the company from R&D stage to potential commercial-stage revenue generation.

Robust, diversified autoimmune pipeline

Compelling Phase 2 MS data plus multiple advancing programs (orelabrutinib Phase 3, oral IL-17 ZB021, novel ZB014) imply multiple franchise opportunities across immune diseases. Pipeline breadth reduces single-product binary risk and supports longer-term growth if clinical programs continue to read out positively.

Low leverage and pre-approval liquidity

Very low debt and a sizable cash/investment balance, supplemented by a Pharmakon non-dilutive facility and ATM proceeds, provide financial flexibility. This runway into 2027 gives management time to pursue filings and initial commercialization without immediate forced dilution, supporting execution on regulatory milestones.

Negative Factors

Large, persistent cash burn

Sustained, large negative operating and free cash flow creates structural funding needs. Continued burn at this magnitude makes the company dependent on capital markets or milestone funding; any delay in approvals or commercialization increases the probability of dilutive financings and constrains reinvestment capacity.

Very weak profitability and revenue decline

A steep fall in revenue and large net losses indicate a cost base far in excess of current commercial receipts. Historical revenue volatility (notably higher in 2023) underscores uncertainty in sustaining sales absent successful product launches, meaning profitability depends on executed commercialization and durable market uptake.

Reliance on contingent funding and equity erosion

Runway assumptions rely on contingent milestone payments, ATM proceeds and debt facilities. If regulatory timing slips or contingencies fail, the company may need to raise capital under less favorable terms. Combined with documented equity erosion, this raises structural dilution and financing risk for executing commercial plans.

Zenas BioPharma, Inc. Business Overview & Revenue Model

Company Description

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.

How the Company Makes Money

null

Zenas BioPharma, Inc. Financial Statement Overview

Summary

Overall financial quality is weak: income statement and cash flow are very poor (revenue down to ~$10M in 2025 with a ~$378M net loss; operating and free cash flow deeply negative at roughly -$172M in 2025), partly offset by a low-debt balance sheet (debt-to-equity ~0.01) with positive equity that reduces near-term leverage risk.

Income Statement

Profitability is very weak and deteriorating: 2025 revenue fell to $10M (down ~33% year over year) and gross profit and net income were deeply negative (net loss of ~$378M). Margins are heavily negative in 2024–2025, reflecting a cost structure far above the current revenue base. A notable positive is that 2023 showed meaningful revenue ($50M) and positive gross profit, but that performance was not sustained, increasing uncertainty around revenue consistency.

Balance Sheet

Leverage is low and the company is not debt-burdened (2025 debt-to-equity ~0.01 with ~$1.3M total debt), which reduces financial risk. Equity is positive and sizable in 2024–2025 (~$312M to ~$242M), supporting balance-sheet flexibility. The key weakness is rapid equity erosion alongside large losses (return on equity strongly negative in 2024–2025), indicating ongoing burn is pressuring the capital base despite limited debt.

Cash Flow

Cash generation is a major concern: operating cash flow and free cash flow are consistently negative and worsening in absolute terms, reaching roughly -$172M in 2025 versus about -$120M in 2024. Free cash flow trends show volatility (improving versus 2024 but still deeply negative), and cash burn broadly tracks the reported net losses, implying the business remains dependent on external funding to sustain operations.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	10.00M	5.00M	50.00M	0.00
Gross Profit	9.94M	-134.14M	50.00M	-61.69M
EBITDA	-211.33M	-163.75M	-27.03M	-75.12M
Net Income	-377.74M	-156.99M	-37.12M	-119.28M
Balance Sheet
Total Assets	383.64M	369.97M	68.18M	74.58M
Cash, Cash Equivalents and Short-Term Investments	343.19M	350.77M	56.86M	67.21M
Total Debt	79.96M	1.00M	21.11M	1.53M
Total Liabilities	141.50M	57.51M	293.90M	266.87M
Stockholders Equity	242.14M	312.46M	-225.72M	-192.29M
Cash Flow
Free Cash Flow	-172.35M	-119.81M	-30.55M	-67.85M
Operating Cash Flow	-172.33M	-119.67M	-30.53M	-65.65M
Investing Cash Flow	-251.89M	-30.55M	-17.00K	-2.20M
Financing Cash Flow	215.28M	412.96M	20.12M	59.39M

Zenas BioPharma, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 23.37
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZBIO, the sentiment is Negative. The current price of 23.37 is below the 20-day moving average (MA) of 25.15, above the 50-day MA of 22.77, and above the 200-day MA of 22.73, indicating a neutral trend. The MACD of -0.29 indicates Positive momentum. The RSI at 42.59 is Neutral, neither overbought nor oversold. The STOCH value of 32.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZBIO.

Zenas BioPharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZBIO	54 Neutral	$1.34B	-4.30	-156.98%	―	―	-38.04%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHAT	50 Neutral	$878.61M	-5.47	55.14%	―	460.30%	33.03%
URGN	49 Neutral	$905.00M	-7.34	170.21%	―	8.00%	-10.15%
VALN	48 Neutral	$895.97M	-5.03	-58.93%	―	14.86%	-1440.45%
RZLT	44 Neutral	$236.37M	-2.69	-64.81%	―	―	26.65%
ABUS	41 Neutral	$840.46M	-28.12	-50.20%	―	116.64%	47.93%

Zenas BioPharma, Inc. Corporate Events

Zenas BioPharma Adopts Amended Short-Term Incentive Plan

On February 10, 2026, Zenas BioPharma’s Board of Directors approved an Amended and Restated Short-Term Incentive Plan, effective January 1, 2026, establishing an annual discretionary cash bonus program for eligible employees based on company performance and individual goal achievement. The plan centralizes broad discretion with the Board, its committees, and senior leadership over eligibility, award determination, payment timing, and interpretation, while subjecting payouts to recoupment policies and allowing the company to amend or discontinue the program, underscoring a flexible but tightly controlled approach to incentive compensation and risk management.

The most recent analyst rating on (ZBIO) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Zenas BioPharma, Inc. stock, see the ZBIO Stock Forecast page.

Zenas BioPharma Announces Positive Phase 3 Obexelimab Results

On January 5, 2026, Zenas BioPharma reported positive top-line data from its global, registration-directed Phase 3 INDIGO trial of obexelimab in immunoglobulin G4-related disease (IgG4-RD), in which 194 patients were randomized 1:1 to obexelimab or placebo over 52 weeks. Obexelimab achieved the primary endpoint with a 56% reduction in the risk of IgG4-RD flare requiring rescue therapy versus placebo and showed highly statistically significant benefit across all four key secondary endpoints, while demonstrating a favorable safety profile with lower rates of serious adverse events and infections than placebo and no new safety signals. Building on these results and prior positive Phase 2 MoonStone data in relapsing multiple sclerosis, Zenas plans to submit a Biologics License Application to the U.S. FDA in the second quarter of 2026 and a Marketing Authorization Application to the EMA in the second half of 2026 for obexelimab in IgG4-RD, positioning the drug as a potential first-line, self-administered B cell–inhibiting therapy in a disease with significant unmet need and reinforcing its status as a potential franchise asset underpinning Zenas’ broader autoimmune pipeline and partnership with Bristol Myers Squibb in key Asia-Pacific markets.

The most recent analyst rating on (ZBIO) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Zenas BioPharma, Inc. stock, see the ZBIO Stock Forecast page.